聖湘生物(688289.SH):2020年度淨利預增6375%到7008%
格隆匯1月18日丨聖湘生物(688289.SH)發佈2020年年度業績預吿,預計2020年年度實現歸屬於母公司所有者的淨利潤與上年同期(法定披露數據)相比,將增加25.17億元到27.67億元,同比增加6375%到7008%。
公司預計2020年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期相比增加24.822億元到27.322億元,同比增加6593%到7257%。
報吿期內,公司積極響應全球抗擊新冠疫情所需,在較短時間內開發出相應疫情防控產品,同步配備專業的售後及技術支持團隊,及時有效地為客户提供全方位的服務,較好地滿足了全球市場需要,進而公司新冠核酸檢測試劑、核酸檢測儀器、相關耗材等產品銷售大幅度增長。同時,公司儀器銷售及裝機增長進一步帶動公司全線試劑的增量銷售,2020年公司全年儀器累計發貨6122台。因此,前述情況對公司2020年年度業績產生了積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.